StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.28−0.00 (-0.74%)

Close on Nov 17, 2026Market cap $53.58MP/E –Yield –

Heron Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Heron Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $12.30M, down 4.3% year over year. For fiscal 2025 it was $12.43M, down 25.5% from the year before. Over ten years it grew -14.7% a year on average. The highest annual figure on record is $174.53M in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$12.43M-25.5%
FY2024Dec 31, 2024$16.68M-57.4%
FY2023Dec 31, 2023$39.13M-52.7%
FY2022Dec 31, 2022$82.70M-36.8%
FY2021Dec 31, 2021$130.82M-25.0%
FY2020Dec 31, 2020$174.53M+4.3%
FY2019Dec 31, 2019$167.38M+19.5%
FY2018Dec 31, 2018$140.03M+1.0%
FY2017Dec 31, 2017$138.58M+34.4%
FY2016Dec 31, 2016$103.13M+68.6%
FY2015Dec 31, 2015$61.18M+11.6%
FY2014Dec 31, 2014$54.83M+68.6%
FY2013Dec 31, 2013$32.52M+114.3%
FY2012Dec 31, 2012$15.17M+84.9%
FY2011Dec 31, 2011$8.21M+13.0%
FY2010Dec 31, 2010$7.26M-6.8%
FY2009Dec 31, 2009$7.80M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.70M-7.9%
Q1 FY2026Mar 31, 2026$2.39M+4.7%
Q4 FY2025Dec 31, 2025$3.75M+17.9%
Q3 FY2025Sep 30, 2025$3.47M-22.3%
Q2 FY2025Jun 30, 2025$2.93M-33.8%
Q1 FY2025Mar 31, 2025$2.28M-50.5%
Q4 FY2024Dec 31, 2024$3.18M-59.3%
Q3 FY2024Sep 30, 2024$4.47M-51.9%
Q2 FY2024Jun 30, 2024$4.43M-66.4%
Q1 FY2024Mar 31, 2024$4.61M-47.8%
Q4 FY2023Dec 31, 2023$7.80M-29.4%
Q3 FY2023Sep 30, 2023$9.29M-63.7%
Q2 FY2023Jun 30, 2023$13.21M-54.2%
Q1 FY2023Mar 31, 2023$8.84M-79.0%
Q4 FY2022Dec 31, 2022$11.06M-61.7%
Q3 FY2022Sep 30, 2022$25.55M-10.7%
Q2 FY2022Jun 30, 2022$28.83M-18.2%
Q1 FY2022Mar 31, 2022$42.07M+10.4%
Q4 FY2021Dec 31, 2021$28.88M-35.0%
Q3 FY2021Sep 30, 2021$28.60M-41.9%
Q2 FY2021Jun 30, 2021$35.23M-19.9%
Q1 FY2021Mar 31, 2021$38.12M+3.3%
Q4 FY2020Dec 31, 2020$44.45M-7.9%
Q3 FY2020Sep 30, 2020$49.18M+41.7%
Q2 FY2020Jun 30, 2020$44.00M+6.2%
Q1 FY2020Mar 31, 2020$36.89M-14.1%
Q4 FY2019Dec 31, 2019$48.28M+21.0%
Q3 FY2019Sep 30, 2019$34.71M+14.1%
Q2 FY2019Jun 30, 2019$41.43M+37.4%
Q1 FY2019Mar 31, 2019$42.97M+8.6%
Q4 FY2018Dec 31, 2018$39.89M-16.5%
Q3 FY2018Sep 30, 2018$30.42M+5.5%
Q2 FY2018Jun 30, 2018$30.16M+5.5%
Q1 FY2018Mar 31, 2018$39.56M+18.5%
Q4 FY2017Dec 31, 2017$47.76M+61.9%
Q3 FY2017Sep 30, 2017$28.84M-4.6%
Q2 FY2017Jun 30, 2017$28.60M–
Q1 FY2017Mar 31, 2017$33.38M–
Q4 FY2016Dec 31, 2016$29.51M–
Q3 FY2016Sep 30, 2016$30.24M–

More Heron Therapeutics figures

See a number that looks wrong?